Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chemocentryx Inc (CCXI)

Chemocentryx Inc (CCXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Chemocentryx Inc 835 INDUSTRIAL ROAD SUITE 600 SAN CARLOS CA 94070 USA

www.chemocentryx.com P: 650-210-2900 F: 650-210-2910

Description:

ChemoCentryx, Inc., being a clinical-stage biopharmaceutical company, focuses on discovering, developing and commercializing orally-administered medications targeted at autoimmune diseases, inflammatory disorders & cancer. Its lead drug, avacopan, is recognized as an adjunctive treatment combined with standard therapy for two main forms of granulomatosis with polyangiitis (GPA) & microscopic polyangiitis (MPA). The drug is marketed under the brand name Tavneos. Avacopan enjoys orphan drug designation in the U.S. and in Europe for treating GPA & MPA.'The company is also developing avacopan in other indications like complement 3 glomerulopathy and hidradenitis suppurativa, and plans to initiate a clinical study to evaluate the candidate in lupus nephritis patients.'Besides avacopan, it is developing CCX559, its orally-administered inhibitor for the treatment of various cancers. ChemoCentryx partnered with Vifor Pharma, providing the latter with exclusive rights to commercialise Tavneos outside the U.S.

Key Statistics

Overview:

Market Capitalization, $K 3,709,799
Enterprise Value, $K 3,468,949
Shares Outstanding, K 71,356
Annual Sales, $ 32,220 K
Annual Net Income, $ -131,760 K
Last Quarter Sales, $ 11,760 K
Last Quarter Net Income, $ -31,650 K
60-Month Beta 1.22
% of Insider Shareholders 8.30%
% of Institutional Shareholders 81.09%
Float, K 65,433
% Float 91.70%
Short Volume Ratio 0.11

Growth:

1-Year Return 54.50%
3-Year Return 558.10%
5-Year Return 642.71%
5-Year Revenue Growth 169.85%
5-Year Earnings Growth -119.77%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.44 on 08/09/22
Latest Earnings Date 11/08/22
Earnings Per Share ttm -1.89
EPS Growth vs. Prev Qtr 20.00%
EPS Growth vs. Prev Year 21.43%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CCXI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -48.52%
Return-on-Assets % -30.59%
Profit Margin % -408.94%
Debt/Equity 0.02
Price/Sales 115.06
Price/Cash Flow N/A
Price/Book 15.68
Book Value/Share 3.31
Interest Coverage -47.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar